Health
Affinity’s COVID-19 antibodies ready for clinical trials – BSA bureau
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
Melbourne-based Affinity Biosciences Pty Ltd (Affinity) has lodged a pre-publication submission to the scientific journal, ‘mAbs’, detailing its results and observations relating to the discovery of potent antibodies against COVID-19.
This can be found at the link,’Anti…
-
General17 hours agoTributes flow after Australian Paralympic bronze medallist Nicholas Hum dies aged 32
-
General13 hours agoNT’s top year 12 achievers celebrated, with some looking to pursue teaching careers
-
General12 hours agoReuven Morrison was killed in the Bondi Beach shooting one year after warning about antisemitism
-
General20 hours agoConsent laws now protect sex workers against non-paying clients